甘露聚糖肽预防手术术后并发感染的荟萃分析
|
摘要
目的系统评价甘露聚糖肽预防手术后并发感染的效果。方法电子检索Cochrane图书馆、MEDLINE、EMBASE、CNKI、CBM,检索日期至2013年2月。纳入甘露聚糖肽预防手术术后感染的临床试验,制订严格的纳入、排除标准,纳入试验研究、评价文献质量、提取数据,并使用Rev Man 5.0软件进行Meta分析。结果纳入11个随机对照试验,结果显示甘露聚糖肽有利于降低患者术后感染的发生率(82.9%比77.4%,OR=1.47,95%CI 1.06~2.04,P=0.02),缩短患者住院时间(均数差为1.37,95%CI-1.68~-1.06,P<0.01),减少患者并发感染的可能(7.6%比20.6%,OR=0.31,95%CI 0.22~0.43,P<0.01)。结论甘露聚糖肽可减少患者术后可能发生的感染,缩短住院时间,其机制可能与提高人体免疫有关。
Objective To evaluate clinical effect of mannatide in the prevention of postoperative infection. Methods Literatures were retrieved from Cochrane Library,MEDLINE,EMBASE,CNKI,CBM databases by computer to February 2013. Trial selection,quality evaluation and information extraction were performed according to including and excluding criteria. Meta-analysis was conducted using Rev Man 5. 0 software. Results Altogether 11 random trials were included in the meta-analysis. The results showed manatide was helpful to decrease the incidence of postoperative infection( 82. 9% vs 77. 4%,OR = 1. 47,95% CI1. 06-2. 04,P = 0. 02),patients' hospitalization time was shortened( SMD = 1. 371. 37,95% CI- 1. 68-- 1. 06,P < 0. 01),the possibility of concurrent infection was reduced( 7. 6% vs 20. 6%,OR = 0. 31,95% CI 0. 22-0. 43,P < 0. 01). Conclusion Mannatide can decrease the postoperative infection rate and hospital stay time,the mechanism of which might associated with improve immunity.
Objective To evaluate clinical effect of mannatide in the prevention of postoperative infection. Methods Literatures were retrieved from Cochrane Library,MEDLINE,EMBASE,CNKI,CBM databases by computer to February 2013. Trial selection,quality evaluation and information extraction were performed according to including and excluding criteria. Meta-analysis was conducted using Rev Man 5. 0 software. Results Altogether 11 random trials were included in the meta-analysis. The results showed manatide was helpful to decrease the incidence of postoperative infection( 82. 9% vs 77. 4%,OR = 1. 47,95% CI1. 06-2. 04,P = 0. 02),patients' hospitalization time was shortened( SMD = 1. 371. 37,95% CI- 1. 68-- 1. 06,P < 0. 01),the possibility of concurrent infection was reduced( 7. 6% vs 20. 6%,OR = 0. 31,95% CI 0. 22-0. 43,P < 0. 01). Conclusion Mannatide can decrease the postoperative infection rate and hospital stay time,the mechanism of which might associated with improve immunity.
引文
[1]Bratzler DW,Houck PM.Antimicrobial prophylaxis for surgery:an advisory statement from the National Surgical Infection Prevention Project[J].Am J Surg,2005,189(4):395-404.
[2]Orasch C,Conen A.Severe primary cytomegalovirus infection in the immunocompetent adult patient:A case series[J].Scand J Infect Dis,2012,44(12):987-991.
[3]Higgins J,Green S.Cochrane handbook for systematic reviews of interventions version 5.0.1(updated September2008)[EB/OL].The Co-chrane Collaboration,2008.Availableat:www.cochranehandbook.org.
[4]张朕华,谢炜,吉蕊,等.甘露聚糖肽对恶性实体肿瘤支持治疗的临床循证研究[J].中国医院药学杂志,2012,32(1):23-29.
[5]李飞,高青山.甘露聚糖肽注射液对肝癌手术患者免疫功能及并发感染的影响[J].中国医药导刊,2013,15(2):288-289.
[6]王志晖,张世荣.甘露聚糖肽注射液对开放性骨折患者免疫功能及并发感染的影响[J].中国医药导刊,2013,15(7):1245-1246.
[7]秦尚学,张晓龙,陈晓斌.甘露聚糖肽注射液在脾切除术中预防感染及临床疗效的观察[J].中国医药导刊,2013,15(6):1006-1007.
[8]何力,林秀峰.甘露聚糖肽注射液对腹外疝患者围手术期免疫功能的影响[J].中国医药导刊,2013,15(2):321-323.
[9]田云鸿,杨红春,王宇,等.单用甘露聚糖肽注射液预防门体静脉分流术感染并发症的临床观察[J].中国医药导刊,2013,15(6):1020-1021.
[10]冯金周,刘发健,刘齐东.甘露聚糖肽应用于颅脑创伤术后感染的临床观察及机制讨论[J].中国医药导刊,2012,14(12):2121-2122.
[11]彭彬,辛大平.甘露聚糖肽注射液降低胆囊切除术后并发感染的临床观察[J].中国医药导刊,2012,14(12):2127-2128.
[12]林秀峰,何力.甘露聚糖肽注射液降低胃肠道肿瘤术后感染发生的临床研究[J].中国医药导刊,2012,14(12):2123-2124.
[13]许稳,耿瑶,尹志良,等.甘露聚糖肽注射液联合抗菌药物预防开放性骨折术后感染的临床观察[J].中国医药导刊,2012,14(12):2129-2130.
[14]李鹤飞,王海波,李永辉,等.甘露聚糖肽对围手术期食管癌患者免疫功能的影响[J].医学研究与教育,2011,28(6):29-31.
[15]李飞,高青山,冯金周.甘露聚糖肽注射液对胆囊癌患者围手术期免疫功能及预防术后感染的价值评估[J].中国医药导刊,2012,14(10):1789-1792.
[16]孙静,胜照杰,贺明霞.力尔凡联合顺铂治疗恶性胸水的临床观察[J].河南肿瘤学杂志,2003,16(3):193-194.
[17]张朕华,吉蕊,郭月芳,等.甘露聚糖肽对淋巴造血系统肿瘤支持治疗的临床荟萃研究[J].中国新药杂志,2011,24(4):15-18.
[18]张可杰.恶性肿瘤患者医院感染相关因素分析[J].中华医院感染学杂志,2001,11(5):36-39.
[2]Orasch C,Conen A.Severe primary cytomegalovirus infection in the immunocompetent adult patient:A case series[J].Scand J Infect Dis,2012,44(12):987-991.
[3]Higgins J,Green S.Cochrane handbook for systematic reviews of interventions version 5.0.1(updated September2008)[EB/OL].The Co-chrane Collaboration,2008.Availableat:www.cochranehandbook.org.
[4]张朕华,谢炜,吉蕊,等.甘露聚糖肽对恶性实体肿瘤支持治疗的临床循证研究[J].中国医院药学杂志,2012,32(1):23-29.
[5]李飞,高青山.甘露聚糖肽注射液对肝癌手术患者免疫功能及并发感染的影响[J].中国医药导刊,2013,15(2):288-289.
[6]王志晖,张世荣.甘露聚糖肽注射液对开放性骨折患者免疫功能及并发感染的影响[J].中国医药导刊,2013,15(7):1245-1246.
[7]秦尚学,张晓龙,陈晓斌.甘露聚糖肽注射液在脾切除术中预防感染及临床疗效的观察[J].中国医药导刊,2013,15(6):1006-1007.
[8]何力,林秀峰.甘露聚糖肽注射液对腹外疝患者围手术期免疫功能的影响[J].中国医药导刊,2013,15(2):321-323.
[9]田云鸿,杨红春,王宇,等.单用甘露聚糖肽注射液预防门体静脉分流术感染并发症的临床观察[J].中国医药导刊,2013,15(6):1020-1021.
[10]冯金周,刘发健,刘齐东.甘露聚糖肽应用于颅脑创伤术后感染的临床观察及机制讨论[J].中国医药导刊,2012,14(12):2121-2122.
[11]彭彬,辛大平.甘露聚糖肽注射液降低胆囊切除术后并发感染的临床观察[J].中国医药导刊,2012,14(12):2127-2128.
[12]林秀峰,何力.甘露聚糖肽注射液降低胃肠道肿瘤术后感染发生的临床研究[J].中国医药导刊,2012,14(12):2123-2124.
[13]许稳,耿瑶,尹志良,等.甘露聚糖肽注射液联合抗菌药物预防开放性骨折术后感染的临床观察[J].中国医药导刊,2012,14(12):2129-2130.
[14]李鹤飞,王海波,李永辉,等.甘露聚糖肽对围手术期食管癌患者免疫功能的影响[J].医学研究与教育,2011,28(6):29-31.
[15]李飞,高青山,冯金周.甘露聚糖肽注射液对胆囊癌患者围手术期免疫功能及预防术后感染的价值评估[J].中国医药导刊,2012,14(10):1789-1792.
[16]孙静,胜照杰,贺明霞.力尔凡联合顺铂治疗恶性胸水的临床观察[J].河南肿瘤学杂志,2003,16(3):193-194.
[17]张朕华,吉蕊,郭月芳,等.甘露聚糖肽对淋巴造血系统肿瘤支持治疗的临床荟萃研究[J].中国新药杂志,2011,24(4):15-18.
[18]张可杰.恶性肿瘤患者医院感染相关因素分析[J].中华医院感染学杂志,2001,11(5):36-39.